563 related articles for article (PubMed ID: 9267827)
1. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
2. Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors.
Ariizumi T; Ogose A; Kawashima H; Hotta T; Li G; Xu Y; Umezu H; Sugai M; Endo N
Pathol Int; 2010 Mar; 60(3):193-202. PubMed ID: 20403045
[TBL] [Abstract][Full Text] [Related]
3. Detection of c-fos expression in benign and malignant musculoskeletal lesions.
Weisstein JS; Majeska RJ; Klein MJ; Einhorn TA
J Orthop Res; 2001 May; 19(3):339-45. PubMed ID: 11398843
[TBL] [Abstract][Full Text] [Related]
4. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.
Scotlandi K; Baldini N; Oliviero M; Di Renzo MF; Martano M; Serra M; Manara MC; Comoglio PM; Ferracini R
Am J Pathol; 1996 Oct; 149(4):1209-19. PubMed ID: 8863670
[TBL] [Abstract][Full Text] [Related]
5. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study.
Oda Y; Naka T; Takeshita M; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2000 Jun; 31(6):709-16. PubMed ID: 10872665
[TBL] [Abstract][Full Text] [Related]
6. Primary bone tumors. MR morphologic appearance correlated with pathologic examinations.
Golfieri R; Baddeley H; Pringle JS; Leung AW; Greco A; Souhami R; Kemp H
Acta Radiol; 1991 Jul; 32(4):290-8. PubMed ID: 1650569
[TBL] [Abstract][Full Text] [Related]
7. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
Huse JT; Pasha TL; Zhang PJ
Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
[TBL] [Abstract][Full Text] [Related]
8. Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype.
Radig K; Häckel C; Herting J; Oda Y; Mittler U; Neumann W; Roessner A
Gen Diagn Pathol; 1997 Feb; 142(3-4):139-45. PubMed ID: 9065577
[TBL] [Abstract][Full Text] [Related]
9. [Cytogenesis and histogenesis of malignant and semimalignant bone tumors].
Roessner A; Grundmann E
Veroff Pathol; 1984; 122():1-195. PubMed ID: 6091360
[TBL] [Abstract][Full Text] [Related]
10. The expression of Met/hepatocyte growth factor receptor gene in giant cell tumors of bone and other benign musculoskeletal tumors.
Ferracini R; Scotlandi K; Cagliero E; Acquarone F; Olivero M; Wunder J; Baldini N
J Cell Physiol; 2000 Aug; 184(2):191-6. PubMed ID: 10867643
[TBL] [Abstract][Full Text] [Related]
11. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
12. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
Li Y; Liang Q; Wen YQ; Chen LL; Wang LT; Liu YL; Luo CQ; Liang HZ; Li MT; Li Z
Cancer Genet Cytogenet; 2010 Apr; 198(2):97-106. PubMed ID: 20362224
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Häkel C; Ueda Y; Tsuchya H; Herrera A; Blasius S; Roessner A
Zentralbl Pathol; 1994 Nov; 140(4-5):363-9. PubMed ID: 7826985
[TBL] [Abstract][Full Text] [Related]
14. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group.
Tallini G; Dorfman H; Brys P; Dal Cin P; De Wever I; Fletcher CD; Jonson K; Mandahl N; Mertens F; Mitelman F; Rosai J; Rydholm A; Samson I; Sciot R; Van den Berghe H; Vanni R; Willén H
J Pathol; 2002 Feb; 196(2):194-203. PubMed ID: 11793371
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of nm23 protein expression in malignant bone tumors.
Oda Y; Walter H; Radig K; Röse I; Neumann W; Roessner A
J Cancer Res Clin Oncol; 1995; 121(11):667-73. PubMed ID: 7593131
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Rushing EJ
Hum Pathol; 2010 May; 41(5):653-62. PubMed ID: 20138330
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of 1355 cases of tumors and tumor-like lesions in the bone].
He XH
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):66-8. PubMed ID: 2364876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
